Pricing Log in Create free account

Nurix Therapeutics, Inc. (NRIX) vs SELLAS Life Sciences Group, Inc. (SLS)

Nurix Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Nurix Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($1.6B and $1.6B). SELLAS Life Sciences Group, Inc. has negative trailing earnings, so its P/E is not meaningful; Nurix Therapeutics, Inc. trades at 6.1×. Nurix Therapeutics, Inc. has the higher net margin (42.0% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Nurix Therapeutics, Inc. leads on 12 and SELLAS Life Sciences Group, Inc. on 2.

Valuation

Metric NRIX SLS Biotechnology median
P/E 6.06 n/m 10.60
P/S 2.42 149.37 9.40
P/B 1.75 11.39 2.13
Price to free cash flow 4.59 n/m 25.18
EV/EBITDA 2.20 n/m 0.66
EV/Sales 0.92 136.22 9.02
Earnings yield 16.50% (2.53%) (32.88%)
Free cash flow yield 21.79% (2.45%) (23.13%)

Profitability

Metric NRIX SLS Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin 41.27% 0.00% 0.00%
Net margin 42.01% 0.00% 0.00%
Free cash flow margin 52.68% 0.00% 0.00%
Return on equity 43.99% (39.63%) (51.96%)
Return on assets 34.33% (36.54%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NRIX SLS Biotechnology median
Revenue growth (TTM) 738.76% — 6.76%
EPS growth (last fiscal year) (5.90%) 50.00% 29.88%
Revenue growth, 5-year CAGR 36.35% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NRIX SLS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.44 18.83 4.97
Net debt to EBITDA 2.14 2.54 1.01

Dividend

Metric NRIX SLS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NRIX SLS Biotechnology median
Market cap 1.62b 1.59b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack